CA3225152A1 - Pyridopyrimidine derivatives useful as wee1 kinase inhibitors - Google Patents

Pyridopyrimidine derivatives useful as wee1 kinase inhibitors Download PDF

Info

Publication number
CA3225152A1
CA3225152A1 CA3225152A CA3225152A CA3225152A1 CA 3225152 A1 CA3225152 A1 CA 3225152A1 CA 3225152 A CA3225152 A CA 3225152A CA 3225152 A CA3225152 A CA 3225152A CA 3225152 A1 CA3225152 A1 CA 3225152A1
Authority
CA
Canada
Prior art keywords
cancer
compound
tumor
lymphoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3225152A
Other languages
English (en)
French (fr)
Inventor
Oren GILAD
Joseph Vacca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aprea Therapeutics Inc
Original Assignee
Aprea Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprea Therapeutics Inc filed Critical Aprea Therapeutics Inc
Publication of CA3225152A1 publication Critical patent/CA3225152A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3225152A 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors Pending CA3225152A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196744P 2021-06-04 2021-06-04
US63/196,744 2021-06-04
PCT/US2022/032203 WO2022256680A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3225152A1 true CA3225152A1 (en) 2022-12-08

Family

ID=82321319

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3225152A Pending CA3225152A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Country Status (10)

Country Link
US (1) US20240254123A1 (https=)
EP (1) EP4347592A1 (https=)
JP (1) JP2024522304A (https=)
KR (1) KR20240044409A (https=)
CN (1) CN117794932A (https=)
AU (2) AU2022287033B2 (https=)
CA (1) CA3225152A1 (https=)
IL (1) IL309037A (https=)
MX (1) MX2023014466A (https=)
WO (1) WO2022256680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315441A (en) 2022-03-07 2024-11-01 Debiopharm Int Sa Treatment methods for small cell lung cancer
IL326854A (en) 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
CN120189510A (zh) * 2023-12-21 2025-06-24 北京哲源科技有限责任公司 一种并环化合物的应用
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CA3071405A1 (en) * 2017-08-01 2019-02-07 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2025204724A1 (en) 2025-07-10
KR20240044409A (ko) 2024-04-04
AU2022287033A1 (en) 2024-01-18
AU2022287033B2 (en) 2025-04-17
CN117794932A (zh) 2024-03-29
WO2022256680A1 (en) 2022-12-08
US20240254123A1 (en) 2024-08-01
IL309037A (en) 2024-02-01
MX2023014466A (es) 2024-05-02
EP4347592A1 (en) 2024-04-10
JP2024522304A (ja) 2024-06-13

Similar Documents

Publication Publication Date Title
AU2022287033B2 (en) Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
AU2014339816B2 (en) Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
KR102258778B1 (ko) 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20240173312A1 (en) Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
CA3066939A1 (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP2023536462A (ja) 変異体リンパ腫を処置する方法
CA2956550A1 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
ES2895419T3 (es) Formas sólidas de (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexan-1-carboxamida y métodos para su uso
EP3436018A1 (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CA3081750A1 (en) Anticancer agents
WO2016161347A1 (en) Combinations for generating tumor-specific immunological memory
US20190142834A1 (en) Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
HK40107981A (zh) 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物
WO2023014518A1 (en) Pharmaceutical compositions and methods for treating neoplasia
CA2845095A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231201

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250325

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250502

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250502

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260302

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260313

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260313

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401